Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia
B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of cancer seen in children and is characterized by a variable clinical course. Although there have been remarkable improvements in the therapy outcomes of pediatric B-ALL, treatment failure remains the leading-cause of death in 1...
Saved in:
Main Author: | Suliman A. Alsagaby (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
by: Ying Wu, et al.
Published: (2022) -
Corrigendum: Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
by: Ying Wu, et al.
Published: (2022) -
Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era
by: Shang Mengxuan, et al.
Published: (2022) -
MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures
by: te Kronnie Geertruy, et al.
Published: (2009) -
CD19-negative B-lineage acute lymphoblastic leukemia: A diagnostic and therapeutic challenge
by: Shashi Bansal, et al.
Published: (2017)